{"id":7387,"date":"2023-04-17T16:23:20","date_gmt":"2023-04-17T16:23:20","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=7387"},"modified":"2023-04-21T16:30:37","modified_gmt":"2023-04-21T16:30:37","slug":"research-grade-biosimilar-antibodies-from-prosci","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/research-grade-biosimilar-antibodies-from-prosci\/","title":{"rendered":"Research Grade Biosimilar Antibodies from ProSci"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Therapeutic antibodies dominate pipelines and top selling drugs at major pharmaceutical companies. They have proven to be valuable tools in the fight against diseases from cancer and autoimmune disorders to infectious and neurodegenerative diseases.<\/p>\n\n\n\n

Beyond therapeutics, monoclonal antibodies shown to be effective in the clinic can help to facilitate laboratory research. Researchers use recombinant monoclonal antibody drug analogues (also known as biosimilars), as tools to research novel new therapies and discover effective off-target applications. With known and approved data on toxicity and efficacy, researchers use these biologics as benchmarks in their studies allowing them to accelerate their findings from bench to clinic. (Read more here<\/a>).<\/p>\n\n\n\n

ProSci-Inc. offers a comprehensive portfolio of high-quality, mammalian-expressed, biosimilar antibodies available to researchers worldwide. Distributed in the UK and Ireland by Caltag Medsystems.<\/p>\n\n\n\n

Jump to research area:<\/p>\n\n\n\n